Table 1 General characteristics of the validation sample according to the registry (n = 747)
Characteristics | |
|---|---|
Age in years at diagnosis | |
Mean (SD) | 58.9 (11.6) |
Median | 59 |
Range | 25–80 |
Age at diagnosis | No of patients (%) |
< 50 years | 165 (22.1) |
50–59 years | 217 (29.0) |
60–69 years | 207 (27.7) |
70–80 years | 158 (21.2) |
Year of diagnosis | No of patients (%) |
1993–1998 | 280 (37.5) |
1999–2004 | 238 (31.9) |
2005–2010 | 229 (30.7) |
Tumor size | No of patients (%) |
≤ 2 cm | 461 (61.7) |
> 2 to ≤ 5 cm | 243 (32.5) |
> 5 cm | 38 (5.1) |
Unknown | 5 (0.7) |
No of metastatic lymph nodes | No of patients (%) |
0 | 406 (54.4) |
1–3 | 171 (22.9) |
4–9 | 92 (12.3) |
≥ 10 | 36 (4.8) |
Unknown | 42 (5.6) |
Histological grade | No of patients (%) |
I | 112 (15.0) |
II | 276 (36.9) |
III | 168 (22.5) |
Unknown (missing or non-evaluable) | 191 (25.6) |
Estrogen receptor (ER) status | No of patients (%) |
Positive | 564 (75.5) |
Negative | 165 (22.1) |
Unknown (missing or non-evaluable) | 18 (2.4) |
Progesterone receptor (PR) status | No of patients (%) |
Positive | 480 (64.3) |
Negative | 248 (33.2) |
Unknown (missing or non-evaluable) | 19 (2.5) |
HER2 status | No of patients (%) |
Positive | 76 (10.2) |
Negative | 392 (52.5) |
Unknown (missing or non-evaluable) | 279 (37.3) |
Laterality | No of patients (%) |
Right | 386 (51.7) |
Left | 345 (46.2) |
Unknown | 16 (2.1) |
Type of breast surgery | No of patients (%) |
Breast-conserving | 443 (59.3) |
Mastectomy | 292 (39.1) |
Unknown | 12 (1.6) |
Sentinel node biopsy | No of patients (%) |
Yes | 168 (22.5) |
No | 579 (77.5) |
Axillary dissection | No of patients (%) |
Yes | 666 (89.2) |
No | 81 (10.8) |
Adjuvant chemotherapy planned | No of patients (%) |
Yes | 257 (34.4) |
No | 490 (65.6) |
Endocrine therapy planned | No of patients (%) |
Yes | 398 (53.3) |
No | 349 (46.7) |
Anti-HER2 therapy planned | No of patients (%) |
Yes | 20 (2.7) |
No | 727 (97.3) |
Radiotherapy planned | No of patients (%) |
Yes | 575 (77.0) |
No | 172 (23.0) |
Recurrence | No of patients (%) |
Any recurrence | 369 (49.4) |
Local recurrence | 132 (17.7) |
Regional recurrence | 41 (5.5) |
Distant recurrence | 228 (30.5) |